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Summary
Objective: The appropriate duration of antibiotic therapy for diabetic foot infections 
(DFI)	 after	 surgical	 amputations	 in	 toto	 is	 debated.	 There	 are	 discrepancies	
worldwide.
Methods: Using	a	clinical	pathway	for	adult	DFI	patients	(retrospective	cohort	analy‐
sis),	we	conducted	a	cluster‐controlled	Cox	regression	analysis.	Minimum	follow‐up	
was 2 months.
Results: We	followed	482	amputated	DFI	episodes	for	a	median	of	2.1	years	after	the	
index	episode.	The	DFIs	predominately	affected	the	forefoot	(n	=	433;	90%).	We	di‐
agnosed	osteomyelitis	 in	239	cases	 (239/482;	50%).	 In	 total,	 47	cases	 (10%)	were	
complicated	by	bacteremia,	 86	 (18%)	by	 abscesses	 and	139	 (29%)	presented	with	
cellulitis.	Surgical	amputation	involved	the	toes	(n	=	155),	midfoot	(280)	and	hindfoot	
(47).	Overall,	178	cases	(37%)	required	revascularization.	After	amputation,	the	me‐
dian	duration	of	antibiotic	administration	was	7	days	(interquartile	range,	1‐16	days).	
In	109	cases	(25%),	antibiotics	were	discontinued	immediately	after	surgery.	Overall,	
clinical	failure	occurred	in	90	DFIs	(17%),	due	to	the	same	pathogens	in	only	38	cases.	
In	multivariate	analysis,	neither	duration	of	total	postsurgical	antibiotic	administra‐
tion	(HR	1.0,	95%	CI	0.99‐1.01)	nor	immediate	postoperative	discontinuation	altered	
failure	rate	(HR	0.9,	0.5‐1.5).
Conclusion: According	 to	 our	 clinical	 pathway,	we	 found	 no	 benefit	 in	 continuing	
postsurgical	antibiotic	administration	in	routine	amputation	for	DFI.	In	the	absence	
of	 residual	 infection	 (ie,	 resection	 at	 clear	 margins),	 antibiotics	 should	 be	
discontinued.
K E Y W O R D S
antibiotic	duration,	diabetic	foot	infections,	failure,	osteomyelitis,	post‐amputation
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1  | INTRODUC TION
Diabetic	 foot	 infections	 (DFIs)1‐3	 frequently	 require	 amputation,	
also	because	of	concomitant	 ischaemia.	 In	these	cases,	surgeons	
and	physicians	 regularly	debate	 the	duration	of	post‐amputation	
antibiotics,	even	in	the	absence	of	residual	clinical	signs	of	infec‐
tion.	Only	 a	 small	minority	of	 stump	complications4,5 are due to 
infections. Clinical practice varies worldwide: centres developed 
strategies	using	microbiological	assessment	of	residual	bone,	sys‐
tematic	empirical	continuation	of	antibiotics	or	case‐by‐case	deci‐
sion.	According	to	an	informal	survey	among	specialized	surgeons	
and	physicians,	 antibiotic	duration	 following	amputation	at	 clear	
margins	varies	between	0	days	and	6	weeks.	Moreover,	the	meth‐
ods	used	to	assess	residual	bone	stump	infection	(biopsy	through	
uninfected area with new sterile instruments vs open biopsy of 
the surgical site6)	also	vary	significantly	(personal communications).
International	guidelines	recommend	post‐amputation	antibiotics	
only	for	remaining	soft	tissue	 infections	and/or	during	a	maximum	
of	2‐5	days,2,7	if	bone	resection	was	achieved	at	“clear	margins”	(low	
grade	 evidence).	However,	 due	 to	high	 rates	of	 poor	outcomes	of	
these	amputation	wounds,1 it is a common practice to prolong an‐
tibiotic	 therapy	 unnecessarily,	 potentially	 resulting	 in	 drug‐related	
adverse	 effects	 and	 costs,	 and	possible	development	of	 antibiotic	
resistance.8 We previously published a retrospective study on the 
continuation	of	antibiotic	prophylaxis	in	leg	amputations	and	found	
no benefit in doing so.5	In	this	study,	we	used	our	clinical	pathway	to	
question	the	continuation	of	post‐amputation	antibiotics.
2  | METHODS
The	Geneva	University	Hospitals	has	a	databank	(clinical	pathway)	
for	DFI.9 The data are prospectively entered and now retrospec‐
tively	 analysed.	 This	 study	 occurred	 between	 1	March	 2014	 and	
30	 April	 2018.	 Surgeons	 in	 the	 orthopaedic	 service	 do	 not	 per‐
form	 routine	microbiological	 assessment	 (histology	 and/or	micro‐
biological	 cultures)	 of	 residual	 bone	 following	 amputation	 and	do	
not use topical antibiotics intraoperatively or on the wounds.10,11 
Specialized	 nurses	 provide	 professional	 wound	 care	 (including	
minimal	 debridement)	 on	 the	ward,	 specifically	 dedicated	 to	 sep‐
tic	orthopaedic	and	amputation	patients.	All	patients	are	actively	
followed up in our clinical pathway. The infectious diseases physi‐
cians and the surgeons deciding the duration of antibiotic therapy 
are	part	of	the	Pathway	Committee.9,12	As	part	of	a	hospital‐wide	
quality	programme,	DFI	patients	participating	 in	the	clinical	path‐
way	 were	 not	 required	 to	 provide	 individual	 consent	 for	 storing	
anonymous	data.	These	patients	also	participated	in	other	DFI	trials	
(Ethical	Committee	No.	13‐178).
2.1 | Definitions and criteria
We	used	DFI	definitions	based	on	the	IDSA	guidelines	criteria,	which	
require	clinical	signs	and	symptoms	of	 inflammation.2 We included 
all	DFI	patients	that	were	amputated	or	disarticulated	in	toto.	Distal	
tibia	 and	 ankle	 amputations	were	 included.	We	excluded	 amputa‐
tions	with	no	clinical	signs	of	 infection,	 regardless	of	microbiology	
results,13	 mid‐tibia	 amputations,	 implant‐related	 DFI	 and	 patients	
with	 <2	months	 of	 active	 follow‐up.	Osteomyelitis	 was	 diagnosed	
using	clinical	features	(eg,	visible	bone),	imaging	(bone	lesions	with‐
out prior surgery or trauma14)	 or	 microbiology	 (bacterial	 growth	
from	surgically	obtained	bone	specimens).	We	defined	clinical	failure	
as	subsequent	episodes	of	DFI	occurring	at	the	same	location	within	
12	months.	DFIs	occurring	later	(ie,	onset	>12	months)	were	arbitrar‐
ily	considered	as	new	episodes.	Microbiological	failure	was	defined	
as	recurrent	DFI	involving	at	least	two	of	three	pathogens	from	the	
index	DFI	 recovered	 in	deep	 tissue	 specimens.	Remission	was	 the	
absence	of	any	clinical,	laboratory	or	radiological	evidence	of	failure	
at	 the	end	of	 follow‐up.	We	considered	antibiotics	 as	broad‐spec‐
trum	if	piperacillin/tazobactam,	glycopeptides,	daptomycin,	carbap‐
enems or cefepime was used.
2.2 | Statistical analyses
We	 performed	 group	 comparisons	 using	 the	 Pearson	 chi‐square	
test	 or	 the	Wilcoxon	 rank‐sum	 test.	 Cox	 regression	 analyses	with	
cluster‐control	(random	effect	at	patients’	level)	determined	associa‐
tions	with	failure.	DFI	episodes	were	censored	at	the	last	follow‐up	
or occurrence of failure. We introduced independent variables hav‐
ing a P value	≤0.05	in	the	univariate	analysis	 in	a	stepwise	fashion	
in	the	multivariate	model	and	checked	for	interaction	(effect	modi‐
fication);	 antibiotic	 administration	was	 automatically	 included	 into	
the	final	model.	Age,	total	duration	of	antibiotic	administration	and	
duration of parenteral therapy were analysed both as continuous 
and	categorical	variables.	The	cut‐off	values	of	the	strata	were	cho‐
sen according to the middle stratum positioned around the median 
value	of	that	variable.	We	used	Stata	software	(9.0,	Stata™,	College	
Station,	TX,	USA).
3  | RESULTS
3.1 | Patients
We	followed	482	DFI	episodes	 involving	amputation	occurring	 in	
258 different patients for a minimal duration of 2 months and a me‐
dian	of	2.1	years	after	the	index	episode	(interquartile	[IQR]	range,	
0.6‐6.5	years).	Median	age	was	71	years,	118	(46%)	patients	were	
female,	median	body	mass	 index	27.5	kg/m2,	median	 index	serum	
C‐reactive	protein	levels	was	89	mg/L	(IQR,	32‐187	mg/L),	median	
glycated	haemoglobin	level	was	7.0	mmol/L	(IQR,	6.1‐8.5	mmol/L),	
median	 transcutaneous	 oxygen	 tension	 was	 42	mm	Hg	 (IQR,	
34‐52	mm	Hg),	 and	 median	 ankle‐brachial	 index	 was	 0.9	 (IQR,	
0.7‐1.2).	 In	 two‐thirds	 (320/482;	66%)	of	 episodes,	 there	was	pe‐
ripheral	arterial	disease	with	signs	of	cutaneous	ischaemia.	In	308	
cases	(64%),	diabetes	was	treated	with	insulin.	Median	duration	of	
diabetes	 was	 15	years	 (IQR,	 7‐23	years).	 Most	 patients	 were	 not	
naïve	regarding	prior	surgery:	overall,	182	patients	(182/258;	71%)	
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had any previous surgical procedure performed on their foot or 
ankle.
3.2 | Infections
The	 DFIs	 predominately	 affected	 the	 forefoot	 (n	=	433;	 90%),	 of	
which	 39	 cases	 involved	 the	 hallux	 only.	We	 localized	 20	DFIs	 in	
the	metatarsal	 region,	 24	 in	 the	 calcaneum,	 and	 five	 in	 the	 ankle;	
there	was	 no	 septic	 arthritis	 of	 the	 ankle.	 Infections	 extended	 to	
the	 distal	 leg	 in	 42	 (9%)	 episodes.	We	 diagnosed	 osteomyelitis	 in	
239	cases	(239/482;	50%),	including	7	with	sequestrae.	In	total,	47	
cases	 (10%)	were	 complicated	 by	 bacteremia,	 86	 (18%)	 presented	
with	 soft	 tissue	 abscesses,	 and	 139	 (29%)	with	 cellulitis.	 By	 noti‐
fying	the	three	most	prevalent	microorganisms	per	DFI	episode	 in	
our	 pathway,	we	 detected	 102	 different	microbiological	 combina‐
tions	 among	 the	 study	 population,	 with	 the	 four	most	 frequently	
identified pathogens being Staphylococcus aureus	 (214	episodes,	of	
which	53	were	methicillin‐resistant15),	enterococci16	(n	=	60),	strep‐
tococci	 (n	=	53)	and	Gram‐negative	pathogens17	 (n	=	190,	of	which	
35 Pseudomonas aeruginosa cases18,19).	Overall,	235	episodes	(49%)	
were polymicrobial.19
3.3 | Amputations and other invasive procedures
Surgical	 amputation	 included	 the	 toes	 (n	=	155),	midfoot	 (n	=	280)	
and	hindfoot	 (n	=	47).	Surgeons	avoided	amputation	across	overtly	
infected	areas.	All	disarticulations	or	amputations	occurred	at	visu‐
ally	 safe	 levels.	 Median	 number	 of	 surgical	 interventions	 was	 1	
(IQR,	1‐1	 intervention),	and	median	 length	of	postsurgical	hospital	
stay	was	34	days	(IQR,	17‐56	days).	All	patients	received	specialized	
wound	care	with	adequate	offloading	during	and	after	hospitaliza‐
tion.	 In	 178	 cases	 (37%),	 endovascular	 revascularization	 was	 per‐
formed,	and	in	64	episodes	(15%),	patients	underwent	30	sessions	
of	hyperbaric	oxygen	therapy.	In	28	episodes	(6%),	vacuum‐assisted	
device was used for wound healing for a median duration of 7 days.
3.4 | Antibiotic administrations
Prior	 to	 admission	or	 initial	 surgical	 procedure,	96	episodes	 (20%)	
already	 received	 systemic	 antibiotic	 therapy,20	 but	 exact	 data	 on	
duration	or	dosage	are	lacking.	Following	amputation,	median	dura‐
tion	of	systemic	antibiotic	administration	was	7	days	(IQR,	1‐16	days)	
and	median	duration	of	parenteral	use	was	5	days	(IQR,	0‐12	days).	
The	entire	antibiotic	course	was	intravenous	in	97	(20%)	cases	and	
oral	 in	69	cases	 (including	perioperatively).	 In	109	cases	 (109/428;	
25%),	 surgeons	 or	 physicians	 discontinued	 antibiotic	 administra‐
tion immediately after amputation. The pathogens of these cases 
were	not	special	or	different	from	DFIs	with	antibiotic	continuation.	
For	 example,	P aeruginosa,18	 acknowledged	 as	 a	major	DFI	 patho‐
gen	leading	to	limb	loss,19	was	as	much	present	in	DFIs	with	direct	
stop	of	post‐amputation	antibiotics	 as	episodes	with	antimicrobial	
continuations	 (7/35	 vs	 102/551,	 P	=	0.83).	 Overall,	 128	 different	
antimicrobial	 regimens	 were	 used,	 of	 which	 144	 (30%)	 included	
broad‐spectrum	 antibiotics.	 The	 five	 most	 frequently	 used	 drugs	
were	 amoxicillin/clavulanate	 (n	=	229),	 quinolones	 (n	=	104;	 18	
cases	as	the	only	monotherapy),	co‐trimoxazole	(n	=	43),	clindamy‐
cin	(n	=	32;	five	episodes	as	the	sole	monotherapy)	and	rifampicin	in	
combination	therapy	(n	=	25).
3.5 | Outcomes
Among	482	amputation	stumps,	clinical	failure	at	the	same	anatomi‐
cal	site	occurred	in	90	cases	(17%)	within	one	year.	However,	only	
38	were	microbiological	 failures	 (ie,	 due	 to	 the	 same	microorgan‐
isms;	 38/482;	 8%).	 There	was	 at	 least	 partial	 concordance	 of	 the	
three dominant pathogens isolated from wound cultures between 
the	initial	and	subsequent	DFI	episodes	in	only	42%	of	cases.	Hence,	
the	majority	of	subsequent	DFI	episodes	(58%)	were	“clinical	recur‐
rences”,	rather	than	“microbiological	recurrences”	according	to	our	
definitions.	Additionally,	progressive	ischaemia	without	clinical	DFI	
occurred	in	38	episodes	(8%).	At	the	end	of	the	study,	86	patients	
had	died	for	various	reasons	unrelated	to	acute	DFI,	even	if	eight	of	
them	were	bacteremic	 (for	another	 infection)	during	 their	hospital	
stay.
Table	1	compares	demographic,	clinical	and	treatment	character‐
istics	for	all	patients,	stratified	according	to	the	outcomes	“clinical”	
vs	“microbiological	recurrence”.	Hereby,	no	variable	was	associated	
with	failure.	Of	note,	neither	total	duration	of	post‐amputation	an‐
tibiotic therapy nor immediate postoperative discontinuation of 
antimicrobials	after	surgery	influenced	failure	rate.	In	the	subgroup	
of	microbiological	failure,	angioplasty	(prior	to	or	immediately	after	
surgery)	was	protective	and	patients	received	antibiotics	for	a	longer	
duration. We found no difference in clinical recurrence according to 
the	various	antibiotics	we	used,	or	when	comparing	the	success	 in	
polymicrobial	DFIs	compared	to	monomicrobial	episodes	(46/109	vs	
185/523; P	=	0.18).	Also,	these	would	be	other	study	questions,	of	
which the results have been published previously.9
3.6 | Multivariate adjustment
In	 view	 of	 the	 considerable	 case‐mix	 inherent	 in	 DFI,	 we	 per‐
formed	 a	 Cox	 regression	 analysis.	 Specifically,	 stump	 failures	
were	 not	 associated	 with	 antibiotic	 therapy‐related	 variations,	
limb	revascularization,	insulin	therapy,	surgical	interventions,	use	
of	vacuum‐assisted	devices,	or	presence	of	abscesses	or	 former	
hindfoot osteomyelitis. Table 2 shows these results for the en‐
tire study population and separately for cases with osteomyelitis. 
Total duration of antibiotic therapy and intravenous antibiotic 
therapy	 (as	continuous	variables)	had	a	hazard	ratio	 (HR)	of	1.0,	
with	 narrow	 confidence	 intervals	 (95%	 CI	 0.99‐1.01).	 Likewise,	
immediate  postoperative discontinuation of antibiotics did not 
influence	 stump	 failure	 (HR	 0.9,	 0.5‐1.5);	 similar	 results	 were	
obtained	 for	 osteomyelitis	 cases	 only	 (HR	 1.0,	 95%	CI	 0.5‐2.1).	
Hyperbaric	oxygen	use	was	protective	in	the	univariate	(HR	2.0;	
95%	CI	1.3‐2.6),	but	not	 in	 the	multivariate	analysis	and	the	os‐
teomyelitis	episodes‐only	analysis	(Table	2).	Finally,	we	repeated	
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theses	multivariate	analyses	for	cases	undergoing	angioplasty.	In	
this	latter	substratum,	total	duration	of	post‐amputation	antibiot‐
ics	or	their	immediate	interruption	equally	did	not	alter	outcomes	
(HR	1.0,	95%	CI	1.0‐1.0)	and	HR	0.4,	95%	CI	0.2‐1.2),	respectively.
4  | DISCUSSION
This	 study	 of	 adult	 DFI	 patients	 from	 a	 defined	 clinical	 pathway	
shows that the duration of antibiotic administration following radi‐
cal amputation did not affect microbiological or clinical failure. This 
was	equally	 true	when	 interrupting	antibiotic	 therapy	 immediately	
after wound closure and when analysing osteomyelitis cases alone.
Our	study,	with	a	total	of	482	amputations	in	the	infected	diabetic	
foot,	is	to	the	best	of	our	knowledge	the	largest	existing	single‐cen‐
tre	database	of	 its	 kind.	 It	 is	 unlikely	 that	our	 findings	 are	 related	
to	 insufficient	sample	size.	Also,	 since	we	 included	all	hospitalized	
patients,	this	study	reflects	real‐life	conditions	at	our	centre's	clinical	
practice,	thus	reducing	selection	bias.	Our	rate	of	clinical	recurrence	
(17%)	is	similar	to	that	reported	in	the	literature	(15%,20	18%21 and 
19%6	depending	on	the	studies).	This	 is	equally	true	regarding	our	
microbiology‐confirmed	recurrence	rate	of	8%,	which	 is	shared	by	
other	groups	(6%‐8%,22	9%,6	and	8%23)	as	well.
The literature on duration of antibiotic therapy in ampu‐
tated	DFI	is	sparse	and	consists	mostly	of	expert	opinions.2,7,24,25 
Available	original	data	mainly	concern	two	questions.	Firstly,	pre‐
vention against surgical site infection26 following major amputa‐
tion,	not	specifically	in	DFI.	Studies	unanimously	advocate	the	use	
of	 prophylactic	 antibiotics	 generally	 for	 0‐48	hours5,27 and up to 
5 days.25,28	 Secondly,	 residual	 infection,	with	 authors	 supporting	
culture	of	 intraoperative	bone	samples	from	residual	stumps,21,29 
rather than from the removed bone.30	 Kowalski	 et	 al21 demon‐
strated	 that	amputated	DFI	patients	with	positive	 resection	mar‐
gins	 for	 residual	osteomyelitis	 (histologically	or	microbiologically)	
revealed	more	 treatment	 failures	 and	 re‐amputations	 than	 those	
without	(44%	vs	15%,	despite	a	similar	2	week	intravenous	antibi‐
otic	 therapy	 in	both	arms).	Atway	et	al	 reported	a	41%	 incidence	
of	positive	bone	resection	margins	among	27	trans‐osseous	ampu‐
tations,	 compared	 to	 a	23%	 incidence	 following	disarticulation.29 
Positive	margins	 were	 associated	with	 worse	 outcome	 despite	 a	
TA B L E  1  Comparison	of	demographic,	clinical	and	treatment	characteristics	of	amputated	patients	with	a	single	episode,	versus	those	
with	subsequent	episodes,	of	diabetic	foot	infection(s)
Total n = 482
Clinical 
remission 
n = 392 P value*
Clinical 
failures 
n = 90
Microbiological 
failure 
n = 38 P value*
Microbiological 
remission 
n = 444
Female	sex 99	(25%) 0.410 19	(21%) 109	(25%) 0.905 9	(24%)
Age	(median) 71 years 0.562 70 years 66 years 0.010 72 years
Body	mass	index	(median) 27.5	kg/m2 0.778 27.6	kg/m2 28.5	kg/m2 0.360 27.4	kg/m2
Glycosylated	haemoglobulin	(median) 7.0	mmol/L 0.864 7.0	mmol/L 8	mmol/L 0.031 7	mmol/L
Transcutaneous	oxygen	(foot;	median) 28 mm Hg 0.580 30 mm Hg 30 mm Hg 0.236 28 mm Hg
Clinical arterial insufficiency 261	(67%) 0.984 59	(66%) 23	(61%) 0.167 297	(71%)
Ankle‐brachial	index	(median) 0.9 0.938 1.0 1.0 0.184 0.9
Bacteremic infection 43	(11%) 0.081 4	(4%) 4	(11%) 0.921 43	(11%)
Serum	C‐reactive	protein	(median) 89	mg/L 0.262 88	mg/L 111	mg/L 0.417 88	mg/L
Insulin‐dependent	diabetes	mellitus 220	(56%) 0.143 54	(60%) 22	(63%) 0.912 252	(64%)
Presence	of	an	abscess 69	(18%) 0.596 17	(19%) 6	(16%) 0.659 80	(16%)
Presence	of	osteomyelitis 188	(48%) 0.136 51	(57%) 24	(63%) 0.081 215	(48%)
Calcaneal osteomyelitis 22	(6%) 0.379 3	(3%) 0	(0%) 0.133 25	(5%)
Presence	of	a	sequestrum 5	(1%) 0.446 2	(2%) 1	(3%) 0.549 6	(2%)
Angioplasty 142	(36%) 0.503 36	(40%) 7	(18%) 0.014 171	(39%)
Number surgical interventions 
(median)
1 0.605 1 1 0.800 1
Duration	antibiotic	treatment	
(median)
15 days 0.139 18 days 23 days 0.001 15 days
>21	days	compared	to	≤21	days 163	(66%) 0.290 43	(48%) 22	(58%) 0.049 184	(41%)
Duration	parenteral	therapy	(median) 5 days 0.809 6 days 5 days 0.571 5 days
>7	days	compared	to	≤7	days 208	(53%) 0.418 52	(58%) 17	(45%) 0.236 243	(55%)
Post‐amputation	antibiotic	stop 90	(23%) 0.705 19	(21%) 6	(16%) 0.295 93	(23%)
*Significant P	values	≤0.05	(two‐tailed).	
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median	 duration	 of	 25	days	 of	 postsurgical	 antibiotic	 therapy.	 In	
contrast,	 side	 results	 of	 a	 Turkish	 prospective	 randomized	multi‐
centre	trial	are	in	line	with	our	findings.	According	to	Saltoğlu	et	al,	
and	provided	a	total	excision	of	infected	bone,	five	days	of	postsur‐
gical	antibiotic	continuation	were	largely	sufficient,23 even if their 
study	was	not	designed	for	the	precise	study	question	of	post‐am‐
putation antibiotic continuation.
Besides the fact that our study is retrospective withloss or 
lack	of	data	for	certain	variables,	it	has	several	limitations.	Firstly,	
patients	 who	 were	 subsequently	 treated	 outside	 of	 our	 centre	
may	have	been	lost	to	follow‐up.	However,	our	centre	is	the	larg‐
est,	and	the	only	public,	hospital	in	the	region	with	a	large	catch‐
ment	area.	 Indeed,	patients	seeking	medical	care	consult	mainly	
at	our	hospital,	making	this	an	unlikely	major	bias.	Secondly,	we	
did	not	analyse	the	antibiotic	agents	that	were	used,	or	the	role	of	
specific	pathogens.	This	is	based	on	the	lack	of	evidence	that	any	
specific systemic antibiotic regimen is significantly superior for 
treatment	of	DFI,	regardless	of	the	involved	pathogens.1,13,15	Our	
study population and pathogens recovered were consistent with 
those reported in the literature.1,6	Moreover,	antibiotic	regimens	
often	 change	 throughout	 treatment	 course	 for	 these	 complex	
cases.	In	our	study,	109	antibiotic	regimens	were	changed	during	
the	course	of	therapy	for	a	given	infection	episode.	Likewise,	we	
did not routinely assess residual stump osteomyelitis in patients 
undergoing	 atrial	 amputation.	 However,	 recent	 studies	 doubt	
about	 the	 accuracy	 of	 these	 specimens,11 especially when they 
were	sampled	through	the	operation	site.	Thirdly,	it	is	noteworthy	
that	wound	 care,	 especially	 pressure	 offloading	 of	 the	 affected	
limb,	is	crucial	for	treating	DFI.1 While the rationale of such mea‐
sures	 is	 easily	 understandable,	 effectively	 implementing	 them	
TA B L E  2  Univariate	and	multivariate	analyses	of	factors	potentially	related	to	failure	in	amputated	diabetic	foot	infections	(cluster‐
controlled	Cox	regression)	(Results expressed as hazard ratios with 95% confidence intervals)
Total n = 482
All episodes n = 482
Only former 
osteomyelitis n = 239
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Female	sex 0.9,	0.5‐1.5 0.9,	0.5‐1.6 1.1,	0.5‐2.1 0.9,	0.5‐2.0
Age	(continuous	variable) 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0,	1.0‐2.0
Age	≥60	y 1.1,	0.6‐2.1 nd 1.2,	0.6‐2.4 nd
Glycosylated	haemoglobin	level 1.0,	0.9‐1.2 nd 1.0,	0.8‐1.2 nd
Insulin	therapy 1.5,	0.9‐2.4 nd 1.2,	0.6‐2.4 nd
Serum	C‐reactive	protein	level 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0.	1.0‐1.0
Bacteremia 0.5,	0.2‐1.3 nd 0.6,	0.2‐1.9 nd
Ankle‐brachial	index 1.0,	0.3‐2.8 nd 0.8,	0.1‐5.4 nd
Transcutaneous	oxygen	(midfoot) 1.0,	1.0‐1.0 nd 1.0,	1.0‐1.0 nd
Transcutaneous	oxygen	(mid‐leg) 1.0,	1.0‐1.0 nd 1.0,	1.0‐1.0 nd
Body	mass	index 1.0,	0.9‐1.1 nd 1.0,	0.9‐1.1 1.0,	0.9‐1.1
Past	history	of	foot	surgery 1.0,	0.9‐1.2 1.0,	0.9‐1.2 0.9,	0.7‐1.1 0.9,	0.6‐1.3
Presence	of	abscess 1.2,	0.7‐2.0 nd 1.2,	0.6‐2.6 nd
Presence	of	osteomyelitis 1.5,	0.9‐2.3 1.4,	0.8‐2.3 nd nd
Metatarsal	amputation	vs.	forefoot 1.1,	0.6‐1.7 nd 1.2,	0.6‐2.3 nd
Ankle	amputation	vs.	forefoot 0.4,	0.1‐1.3 nd 0.6,	0.1‐2.6 nd
Number surgical interventions 0.9,	0.7‐1.1 0.9,	0.7‐1.2 1.1,	0.8‐1.5 1.2,	0.9‐1.7
Angioplasty 1.1,	0.7‐1.7 1.0,	0.6‐1.7 1.0,	0.5‐1.9 1.3,	0.6‐3.0
Vacuum‐assisted	closure 1.0,	0.9‐1.1 nd 1.1,	0.9‐1.2 nd
Duration	total	antibiotic	administration 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0,	1.0‐1.0 1.0,	1.0‐1.0
>1‐≤3	d	compared	to	0	d 0.8,	0.4‐1.6 0.9,	0.5‐1.9 0.9,	0.4‐2.1 1.1,	0.5‐2.8
>3‐≤7	d	compared	to	0	d 0.6,	0.3‐1.3 0.7,	0.3‐1.6 0.5,	0.2‐1.4 0.6,	0.2‐1.8
>7‐≤14	d	compared	to	0	d 1.1,	0.6‐2.0 1.4,	0.7‐2.8 0.9,	0.4‐1.9 1.1,	0.5‐2.9
Duration	parenteral	administration 1.0,	1.0‐1.0 nd 1.0,	1.0‐1.0 nd
>1	wk	IV	antibiotic	therapy 1.3,	0.8‐2.1 nd 1.7,	0.9‐3.2 nd
Immediate	stopping	post‐amputation 1.0,	0.6‐1.7 0.9,	0.5‐1.5 1.3,	0.6‐2.5 1.0,	0.5‐2.1
Hyperbaric	oxygen	therapy 2.0, 1.2‐3.6 1.9,	0.9‐4.2 1.9,	0.8‐4.3 1.7,	0.6‐4.7
nd,	not	done.
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depends	on	the	patient's	adherence,	which	we	could	not	monitor	
in	our	assessment.	Fourthly,	we	defined	remission	as	the	absence	
of	any	clinical,	radiological	or	laboratory	signs	of	recurrent	or	new	
DFI	at	the	site	of	prior	infection,	within	one	year	following	treat‐
ment	 of	 the	 prior	DFI	 episode.	 In	DFI,	microbiological	 patterns	
of	consecutive	DFI	episodes	are	only	congruent	in	two‐thirds	of	
cases	 at	most,31	 and	 new	 ischaemia,	 noncompliance,	 as	well	 as	
inadequate	anatomical	positioning	may	lead	to	new	infections	at	
the	same	location.	Hence,	we	overestimate	the	true	risk	of	recur‐
rence	 having	more	 to	 do	with	 patient's	 compliance	 or	 progres‐
sive ischaemia1	rather	than	with	antibiotic	effects.	Fifthly,	there	
is	 certainly	 bias	 from	 confounding	 by	 indication;	 for	 example,	
patients who were suspected to have an unfavourable outcome 
might be those who were prescribed longer antibiotic courses. 
Only	prospective	randomized	trials	could	help	to	fully	circumvent	
this	bias	inherent	to	every	retrospective	study.	Therefore,	we	re‐
nounced on formal propensity score analyses in our very hetero‐
geneous	 study	 population.	 Finally,	 we	 included	 all	 DFI	 patients	
hospitalized	for	in	toto	amputations	in	order	to	reproduce	routine	
clinical	 settings	 at	 best.	 This	 should	not	 be	 confused	with	DFIs	
with	proven	postsurgical	residual	osteomyelitis.	For	this	specific	
population,	continuation	of	systemic	antibiotic	for	3‐4	weeks21 is 
warranted.
In	 conclusion,	 in	 our	 daily	 practice	 clinical	 pathway	 including	
482	 consecutive	 DFIs,	 continuation	 of	 postsurgical	 antibiotic	 ad‐
ministration or immediate interruption was not associated with 
treatment	 failure,	 provided	 that	 surgeons	 performed	 amputations	
with	clear	bone	margins.	Therefore,	favouring	efficacious	antibiotic	
stewardship	 in	 the	DFI	 population,8 our findings support immedi‐
ate	interruption	of	antibiotic	therapy	following	routine	amputations,	
provided that residual infection is absent.
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